Oxymetazoline - RDD Pharma

Drug Profile

Oxymetazoline - RDD Pharma

Alternative Names: RDD 0315

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator RDD Pharma
  • Class Decongestants; Imidazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Alpha adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Faecal incontinence

Most Recent Events

  • 21 Feb 2017 RDD Pharma has patent protection for oxymetazolinein the EU, China, Israel and Russia
  • 21 Feb 2017 RDD Pharma has patents pending for oxymetazoline in USA, Japan, Australia, Brazil, Canada and India
  • 21 Feb 2017 RDD Pharma completes phase IIa trial in faecal incontinence in the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top